Praxis Precision Medicines Provides Portfolio Update at 2023

Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 program for...

Related Keywords

Tennessee , United States , Boston , Massachusetts , Marcio Souza , Albertoj Espay , Linkedin , Grossman School Of Medicine , Rogcon Inc , Globenewswire Inc , European Medicines Agency , Praxis Precision Medicines Inc , Drug Administration , Exchange Commission , Joana Gardner Center , Epilepsy Study Consortium , University Of Cincinnati , Ionis Pharmaceutics Inc , Nasdaq , Facebook , Precision Medicines , Endowed Chair , Daily Living , New Drug Application , Maximal Electroshock Seizure Model , Orphan Drug Designation , Rare Pediatric Disease Designation , Medicines Agency , Praxi Cerebrum , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Although Praxi , Stone Evoke Canale , Markets ,